How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Volumn 6, Issue 4, 2000, Pages 293-295

  Bell, D S ^a   Ovalle, F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RETREATMENT; RETROSPECTIVE STUDY; TIME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; RETREATMENT; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS;

MLCS; MLOWN;

EID: 0034231813     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.6.4.293     Document Type: Article

References (0)